Last reviewed · How we verify
MnSOD Mimetic BMX-001
At a glance
| Generic name | MnSOD Mimetic BMX-001 |
|---|---|
| Also known as | BMX-001, Manganese (III) ortho N-Butoxyethylpyridylporphyrin, Manganese Butoxyethyl Pyridyl Porphyrin, Mitochondrial Manganese Superoxide Dismutatse Mimetic BMX-001, Mn(III) meso-tetrakis(N-n-butoxyethylpyridinium-2-yl)porphyrin |
| Sponsor | NRG Oncology |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer (PHASE2)
- Safety Study of BMX-001 (Radio-protector) in Patients With Newly Diagnosed Anal Cancer (PHASE1, PHASE2)
- Trial of the Efficacy and Safety of Short and Long Course Radiation Therapy With/Without BMX-001 (PHASE2)
- Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001 (PHASE1, PHASE2)
- BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer (PHASE1, PHASE2)
- A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy (PHASE1, PHASE2)
- A Trial of Concurrent Radiation Therapy, Cisplatin, and BMX-001 in Locally Advanced Head and Neck Cancer (PHASE1, PHASE2)
- Trial of BMX-001 or Placebo in Head and Neck Cancer Patients (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MnSOD Mimetic BMX-001 CI brief — competitive landscape report
- MnSOD Mimetic BMX-001 updates RSS · CI watch RSS
- NRG Oncology portfolio CI